aspirin has been researched along with Peripheral Vascular Diseases in 146 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Peripheral Vascular Diseases: Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with clopidogrel results in a significant decrease in the need for rehospitalization for ischemic events or bleeding compared with aspirin." | 9.09 | Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000) |
| "After successful PTA, 275 patients with symptomatic peripheral arterial disease (claudication or critical limb ischemia) and femoropopliteal obstructions were randomized to receive either 2500 IU of dalteparin subcutaneously for 3 months plus 100 mg of aspirin daily (n = 137), or 100 mg aspirin daily alone (n = 138)." | 5.12 | Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial. ( Amann-Vesti, BR; Banyai, M; Koppensteiner, R; Meier, T; Pfammatter, T; Rousson, V; Spring, S; van der Loo, B, 2006) |
| " The rate of cardiovascular death, MI, or stroke was significantly lower in the clopidogrel plus aspirin arm than in the placebo plus aspirin arm: 7." | 5.12 | Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. ( Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Fabry-Ribaudo, L; Flather, MD; Fox, KA; Hacke, W; Hamm, CW; Hankey, GJ; Hu, T; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA, 2007) |
| "We studied 18 558 patients with ischemic stroke, myocardial infarction, or peripheral arterial disease who participated in the trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE), a study that compared the occurrence of ischemic stroke, myocardial infarction, or vascular death under randomized treatment with aspirin or clopidogrel." | 5.11 | Leukocyte count as an independent predictor of recurrent ischemic events. ( Boddy, AW; Brandt, T; Buggle, F; Dukovic, DA; Grau, AJ; Hacke, W; Lichy, C, 2004) |
| "Treatment with clopidogrel results in a significant decrease in the need for rehospitalization for ischemic events or bleeding compared with aspirin." | 5.09 | Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000) |
| "Aspirin use in PVD might not be associated with improved cardiovascular outcomes or worse bleeding outcomes." | 4.95 | Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials. ( Bavry, AA; Elgendy, AY; Elgendy, IY; Mahmoud, AN; Mahtta, D; Rambarat, C, 2017) |
| " Monotherapy with either aspirin or clopidogrel, reduces the rate of stroke, myocardial infarction, and cardiovascular death in patients suffering from peripheral arterial disease." | 4.85 | Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy? ( Milani, RV, 2009) |
| "Appropriate oral first-line antiplatelet therapy is aspirin for individuals with ST-segment elevation myocardial infarction; aspirin or clopidogrel for those with TIA or stroke, chronic stable angina, or peripheral arterial disease; and aspirin combined with clopidogrel for those with non-ST-segment elevation acute coronary syndrome." | 4.82 | Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. ( Anand, SS; Tran, H, 2004) |
| "We studied 137 patients undergoing antiplatelet therapy with clopidogrel and 336 patients with aspirin for the occurrence of neurological events (ischemic stroke and/or carotid revascularization)." | 3.73 | Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. ( Amighi, J; Brunner, M; Exner, M; Felber, K; Funk, M; Mannhalter, C; Minar, E; Mlekusch, W; Müller, M; Sabeti, S; Schillinger, M; Ziegler, S, 2005) |
| "People without symptoms but at increased risk of a coronary heart disease event (> 1% annual risk) may reduce this risk by taking low-dose aspirin." | 3.72 | Aspirin for cardiovascular disease prevention. ( Hung, J, 2003) |
| "Aspirin was not a significant factor in preventing graft failure or vascular death in patients undergoing bypass for critical limb ischemia." | 3.72 | The efficacy of aspirin in patients undergoing infra-inguinal bypass and identification of high risk patients. ( Edwards, AT; Mahmood, A; Simms, MH; Sintler, M; Smith, SR; Vohra, RK, 2003) |
| "(1) Aspirin reduces the risk of myocardial infarction in men over 40 with no history of cardiovascular disease, and in hypertensive patients of both sexes over that age." | 3.70 | Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention. ( , 2000) |
| "Major bleeding was associated with a 3-fold increased risk of subsequent ischemic events (crude hazard ratio, 3." | 2.74 | Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. ( Algra, A; Eikelboom, BC; Lawson, JA; Moll, FL; Tangelder, MJ; van Hattum, ES, 2009) |
| "The benefits of the long-term administration of oral anticoagulant therapy remain unclear in patients with lower extremity arterial bypass surgery." | 2.70 | Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. ( Johnson, WC; Williford, WO, 2002) |
| "Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events." | 2.68 | A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. ( , 1996) |
| " These data indicate that chronic administration of low-dose aspirin to apparently healthy men reduced the need for peripheral arterial surgery." | 2.67 | Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. ( Buring, JE; Goldhaber, SZ; Hennekens, CH; LaMotte, F; Manson, JE; Rosner, B; Stampfer, MJ, 1992) |
| "For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched June 2014) and the Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 5)." | 2.52 | Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. ( Acosta, S; Bedenis, R; Lethaby, A; Maxwell, H; Prins, MH, 2015) |
| "Aspirin therapy was associated with a reduction in the secondary outcome of nonfatal stroke (52 of 2823 vs 76 of 2446; RR, 0." | 2.45 | Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. ( Berger, JS; Hiatt, WR; Kittelson, JM; Krantz, MJ, 2009) |
| "Aspirin has been the cornerstone of antiplatelet therapy for many decades, but in recent years, adenosine diphosphate (ADP) receptor antagonists, mainly clopidogrel and ticlopidine, and glycoprotein (GP) IIb/IIIa (integrin alpha IIb beta 3) inhibitors have also shown similar effectiveness." | 2.44 | Acute and long-term antiplatelet therapy. ( Goudevenos, JA; Mikhailidis, DP; Papathanasiou, AI; Tselepis, AD, 2008) |
| "As well as initiating thrombus formation at the site of a ruptured atherosclerotic plaque, platelets play a key role in vascular inflammation, through release of their own pro-inflammatory mediators and interactions with other relevant cell types (endothelial cells, leukocytes, and smooth muscle cells)." | 2.44 | Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. ( Badimon, JJ; Bhatt, DL; Herbert, JM; Lüscher, TF; Steinhubl, SR, 2007) |
| "We searched the Cochrane Peripheral Vascular Diseases Group's trials register (last searched April 2004), the Cochrane Central Register of Controlled trials (CENTRAL Issue 2, 2004), MEDLINE and EMBASE (last searched June 2004)." | 2.43 | Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. ( Büller, HR; Dörffler-Melly, J; Koopman, MM; Prins, MH, 2005) |
| " These results demonstrated that long-term administration of clopidogrel was effective in preventing ischaemic events in patients with atherosclerotic vascular disease including PAD." | 2.41 | Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy. ( Hiatt, WR, 2002) |
| "A 50-year-old woman with a history of Crohn's disease treated with adalimumab presented with left hand pain and duskiness." | 1.56 | Digital ischaemia secondary to adalimumab-induced antiphospholipid syndrome. ( Cheemalavagu, S; Knight, JS; McCoy, SS, 2020) |
| "Hypertension is a common risk factor for peripheral arterial disease (PAD)." | 1.36 | Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. ( Anderson, RD; Bavry, AA; Cooper-Dehoff, RM; Denardo, SJ; Gong, Y; Handberg, EM; Pepine, CJ, 2010) |
| "There is a high prevalence of uncontrolled (treated or untreated) cardiovascular risk factors in patients undergoing planned peripheral vascular reconstruction, and chronic use of aspirin is associated with reduced all-cause mortality in these patients." | 1.35 | Profile of cardiovascular risk factors and mortality in patients with symptomatic peripheral arterial disease. ( Giannini, M; Matsubara, BB; Matsubara, LS; Mouraria, GG; Zanati, SG, 2009) |
| "No or only a mild restenosis developed in 27 patients." | 1.32 | Clinical and angiographic outcome after interventional treatment of the iliac arteries with a new carbofilm coated stent: preliminary results. ( Butz, B; Feuerbach, S; Lenhart, M; Link, J; Paetzel, C; Pfister, K; Schleicher, T; Stern, U, 2004) |
| " It is indicated, at a dosage of 75 mg/day, for the reduction of atherosclerotic events including myocardial infarction, ischaemic stroke and vascular death in patients with atherosclerosis manifested by recent stroke, myocardial infarction or established peripheral vascular disease." | 1.31 | [Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)]. ( Scheen, AJ, 2001) |
| "At reexamination, one thrombus was detected in the patient without anticoagulant treatment and one thrombus was detected in the 8 patients treated with aspirin (13%), compared with ten thrombi detected in the 20 patients (50%) treated with phenprocoumon (p = NS)." | 1.29 | Left atrial thrombi despite anticoagulant and antiplatelet therapy. ( Erbel, R; Genth, S; Meyer, J; Pinnau, U; Zotz, RJ, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 28 (19.18) | 18.2507 |
| 2000's | 95 (65.07) | 29.6817 |
| 2010's | 21 (14.38) | 24.3611 |
| 2020's | 2 (1.37) | 2.80 |
| Authors | Studies |
|---|---|
| Brunetti, ND | 1 |
| De Gennaro, L | 1 |
| Di Biase, M | 1 |
| Caldarola, P | 1 |
| Cheemalavagu, S | 1 |
| McCoy, SS | 1 |
| Knight, JS | 1 |
| Clarkson, SA | 1 |
| Heindl, B | 1 |
| Cai, A | 1 |
| Beasley, M | 1 |
| Dillon, C | 1 |
| Limdi, N | 1 |
| Brown, TM | 1 |
| Mahmoud, AN | 1 |
| Elgendy, AY | 1 |
| Rambarat, C | 1 |
| Mahtta, D | 1 |
| Elgendy, IY | 1 |
| Bavry, AA | 2 |
| Karnabatidis, D | 2 |
| Spiliopoulos, S | 2 |
| Pastromas, G | 2 |
| Kitrou, P | 2 |
| Christeas, N | 1 |
| Katsanos, K | 2 |
| Siablis, D | 2 |
| Diamantopoulos, A | 1 |
| Creager, MA | 3 |
| Bedenis, R | 1 |
| Lethaby, A | 1 |
| Maxwell, H | 1 |
| Acosta, S | 1 |
| Prins, MH | 2 |
| Clark, CE | 1 |
| Taylor, RS | 1 |
| Butcher, I | 1 |
| Stewart, MC | 1 |
| Price, J | 1 |
| Fowkes, FG | 1 |
| Shore, AC | 1 |
| Campbell, JL | 1 |
| Ghantous, AE | 1 |
| Ferneini, EM | 1 |
| Papathanasiou, AI | 1 |
| Goudevenos, JA | 1 |
| Mikhailidis, DP | 8 |
| Tselepis, AD | 1 |
| de Liefde, II | 2 |
| Hoeks, SE | 3 |
| van Gestel, YR | 3 |
| Bax, JJ | 2 |
| Klein, J | 2 |
| van Domburg, RT | 2 |
| Poldermans, D | 3 |
| Belch, J | 1 |
| MacCuish, A | 1 |
| Campbell, I | 1 |
| Cobbe, S | 1 |
| Taylor, R | 1 |
| Prescott, R | 1 |
| Lee, R | 2 |
| Bancroft, J | 1 |
| MacEwan, S | 1 |
| Shepherd, J | 1 |
| Macfarlane, P | 1 |
| Morris, A | 1 |
| Jung, R | 1 |
| Kelly, C | 1 |
| Connacher, A | 1 |
| Peden, N | 1 |
| Jamieson, A | 1 |
| Matthews, D | 1 |
| Leese, G | 1 |
| McKnight, J | 1 |
| O'Brien, I | 1 |
| Semple, C | 1 |
| Petrie, J | 1 |
| Gordon, D | 1 |
| Pringle, S | 1 |
| MacWalter, R | 1 |
| Verhagen, HJ | 1 |
| Cleland, JG | 1 |
| Elwood, P | 1 |
| Cacoub, PP | 1 |
| Bhatt, DL | 4 |
| Steg, PG | 2 |
| Topol, EJ | 3 |
| Price, HC | 1 |
| Holman, RR | 1 |
| Milani, RV | 1 |
| Mohler, ER | 1 |
| Linnemann, B | 2 |
| Prochnow, S | 1 |
| Mani, H | 2 |
| Schwonberg, J | 2 |
| Lindhoff-Last, E | 2 |
| Berger, JS | 2 |
| Krantz, MJ | 5 |
| Kittelson, JM | 1 |
| Hiatt, WR | 7 |
| McDermott, MM | 2 |
| Criqui, MH | 2 |
| Zanati, SG | 1 |
| Mouraria, GG | 1 |
| Matsubara, LS | 1 |
| Giannini, M | 1 |
| Matsubara, BB | 1 |
| Takagi, H | 1 |
| Umemoto, T | 1 |
| Wilson, AM | 1 |
| Brittenden, J | 1 |
| Bachoo, P | 1 |
| Ford, I | 1 |
| Nixon, GF | 1 |
| van Hattum, ES | 1 |
| Algra, A | 2 |
| Lawson, JA | 1 |
| Eikelboom, BC | 2 |
| Moll, FL | 1 |
| Tangelder, MJ | 2 |
| Vavra, AK | 1 |
| Kibbe, MR | 1 |
| Anderson, RD | 1 |
| Gong, Y | 1 |
| Denardo, SJ | 1 |
| Cooper-Dehoff, RM | 1 |
| Handberg, EM | 1 |
| Pepine, CJ | 1 |
| Scholte op Reimer, WJ | 1 |
| Schouten, O | 1 |
| Lenzen, MJ | 1 |
| Flu, WJ | 1 |
| van Kuijk, JP | 1 |
| Latour, C | 1 |
| van Urk, H | 2 |
| Rechner, AR | 1 |
| Poredos, P | 2 |
| Jezovnik, MK | 1 |
| Shigematsu, H | 1 |
| Nishibe, T | 1 |
| Obitsu, Y | 1 |
| Matsuzaki, K | 1 |
| Ishida, A | 1 |
| Miyata, T | 1 |
| Shindo, S | 1 |
| Hida, K | 1 |
| Ohta, T | 1 |
| Ando, M | 1 |
| Kawasaki, T | 1 |
| Yasugi, T | 1 |
| Matsumoto, T | 1 |
| Beckman, JA | 1 |
| Norgren, L | 2 |
| Bergqvist, D | 3 |
| Pärsson, H | 1 |
| Belch, JJ | 1 |
| Dormandy, J | 1 |
| Biasi, GM | 1 |
| Biasi, BM | 1 |
| Cairols, M | 1 |
| Diehm, C | 1 |
| Eikelboom, B | 1 |
| Golledge, J | 1 |
| Jawien, A | 1 |
| Lepäntalo, M | 1 |
| Becquemin, JP | 1 |
| Clement, D | 1 |
| Baumgartner, I | 1 |
| Minar, E | 4 |
| Stonebridge, P | 1 |
| Vermassen, F | 1 |
| Matyas, L | 1 |
| Leizorovicz, A | 1 |
| Schmidt, T | 1 |
| Tsakiris, DA | 1 |
| Grapow, M | 1 |
| Siegemund, M | 1 |
| Gale, CP | 1 |
| Metcalfe, E | 1 |
| West, RM | 1 |
| Das, R | 1 |
| Kilcullen, N | 1 |
| Morrell, C | 1 |
| Crook, R | 1 |
| Batin, PD | 1 |
| Hall, AS | 1 |
| Barth, JH | 1 |
| Thomson, L | 1 |
| Monaco, M | 1 |
| Di Tommaso, L | 1 |
| Pinna, GB | 1 |
| Lillo, S | 1 |
| Schiavone, V | 1 |
| Stassano, P | 1 |
| Allemang, MT | 1 |
| Rajani, RR | 1 |
| Nelson, PR | 1 |
| Hingorani, A | 1 |
| Kashyap, VS | 2 |
| Macchi, L | 1 |
| Brizard, A | 1 |
| Christiaens, L | 1 |
| Herpin, D | 1 |
| Emmerich, J | 1 |
| Guralnik, JM | 1 |
| Greenland, P | 1 |
| Pearce, WH | 1 |
| Liu, K | 1 |
| Taylor, L | 1 |
| Chan, C | 1 |
| Sharma, L | 1 |
| Schneider, JR | 1 |
| Ridker, PM | 4 |
| Green, D | 1 |
| Quann, M | 1 |
| Matsagas, MI | 3 |
| Jagroop, IA | 4 |
| Geroulakos, G | 4 |
| Dörffler-Melly, J | 2 |
| Schmidli, J | 1 |
| Mahler, F | 1 |
| Cotter, G | 1 |
| Cannon, CP | 1 |
| McCabe, CH | 1 |
| Michowitz, Y | 1 |
| Kaluski, E | 1 |
| Charlesworth, A | 1 |
| Milo, O | 1 |
| Bentley, J | 1 |
| Blatt, A | 1 |
| Krakover, R | 1 |
| Zimlichman, R | 1 |
| Reisin, L | 1 |
| Marmor, A | 1 |
| Lewis, B | 1 |
| Vered, Z | 1 |
| Caspi, A | 1 |
| Braunwald, E | 1 |
| Sellmayer, A | 1 |
| Limmert, T | 1 |
| Hoffmann, U | 1 |
| Matsagas, M | 1 |
| Bowbrick, VA | 1 |
| Stansby, G | 3 |
| Hung, J | 1 |
| Lawson, J | 1 |
| Ziegler, S | 2 |
| Alt, E | 1 |
| Brunner, M | 2 |
| Speiser, W | 1 |
| Mahmood, A | 1 |
| Sintler, M | 1 |
| Edwards, AT | 1 |
| Smith, SR | 1 |
| Simms, MH | 1 |
| Vohra, RK | 1 |
| Weston, C | 1 |
| Rao, U | 1 |
| Smout, JD | 1 |
| Shenton, BK | 1 |
| Grau, AJ | 1 |
| Boddy, AW | 1 |
| Dukovic, DA | 1 |
| Buggle, F | 1 |
| Lichy, C | 1 |
| Brandt, T | 1 |
| Hacke, W | 3 |
| Aronow, WS | 1 |
| Gresele, P | 1 |
| Migliacci, R | 1 |
| Neri Serneri, GG | 1 |
| Coccheri, S | 1 |
| Marubini, E | 1 |
| Violi, F | 3 |
| Tran, H | 1 |
| Anand, SS | 1 |
| Butz, B | 1 |
| Paetzel, C | 1 |
| Stern, U | 1 |
| Schleicher, T | 1 |
| Pfister, K | 1 |
| Link, J | 1 |
| Feuerbach, S | 1 |
| Lenhart, M | 1 |
| Koopman, MM | 1 |
| Büller, HR | 1 |
| Eriksson, P | 1 |
| Madi-Jebara, S | 1 |
| Rkeiby-Kassabian, N | 1 |
| Yazigi, A | 1 |
| Schillinger, M | 1 |
| Funk, M | 1 |
| Felber, K | 1 |
| Exner, M | 1 |
| Mlekusch, W | 1 |
| Sabeti, S | 1 |
| Amighi, J | 1 |
| Müller, M | 1 |
| Mannhalter, C | 1 |
| Hackam, DG | 2 |
| Hansen, DB | 1 |
| Vahl, AC | 1 |
| Reekers, JA | 1 |
| Coronel, SM | 1 |
| Eikelboom, JW | 1 |
| Hankey, GJ | 2 |
| Thom, J | 1 |
| Claxton, A | 1 |
| Yi, Q | 1 |
| Gilmore, G | 1 |
| Staton, J | 1 |
| Barden, A | 1 |
| Norman, PE | 1 |
| Tulsyan, N | 1 |
| Ouriel, K | 1 |
| Wong, S | 1 |
| Morel-Kopp, MC | 1 |
| Chen, Q | 1 |
| Appleberg, M | 1 |
| Ward, CM | 1 |
| Lewis, DR | 1 |
| Rao, AK | 1 |
| Vaidyula, VR | 1 |
| Bagga, S | 1 |
| Jalagadugula, G | 1 |
| Gaughan, J | 1 |
| Wilhite, DB | 1 |
| Comerota, AJ | 2 |
| Koppensteiner, R | 2 |
| Spring, S | 1 |
| Amann-Vesti, BR | 1 |
| Meier, T | 1 |
| Pfammatter, T | 1 |
| Rousson, V | 1 |
| Banyai, M | 1 |
| van der Loo, B | 1 |
| Spencer, FA | 1 |
| Lessard, D | 1 |
| Doubeni, C | 1 |
| Yarzebski, J | 1 |
| Gore, JM | 1 |
| Goldberg, RJ | 1 |
| Priollet, P | 1 |
| de Pouvourville, G | 1 |
| Catalano, M | 1 |
| Born, G | 1 |
| Peto, R | 1 |
| Blinc, A | 1 |
| Flather, MD | 1 |
| Berger, PB | 1 |
| Black, HR | 1 |
| Boden, WE | 1 |
| Cacoub, P | 1 |
| Cohen, EA | 1 |
| Easton, JD | 1 |
| Hamm, CW | 1 |
| Johnston, SC | 1 |
| Mak, KH | 1 |
| Mas, JL | 1 |
| Montalescot, G | 1 |
| Pearson, TA | 1 |
| Steinhubl, SR | 2 |
| Weber, MA | 1 |
| Fabry-Ribaudo, L | 1 |
| Hu, T | 1 |
| Fox, KA | 1 |
| Krayenbuehl, PA | 1 |
| Wiesli, P | 1 |
| Schmid, M | 1 |
| Schmid, C | 1 |
| Ehses, JA | 1 |
| Hersberger, M | 1 |
| Vetter, W | 1 |
| Schulthess, G | 1 |
| Thatipelli, MR | 1 |
| Pellikka, PA | 1 |
| McBane, RD | 1 |
| Rooke, TW | 1 |
| Rosales, GA | 1 |
| Hodge, D | 1 |
| Herges, RM | 1 |
| Wysokinski, WE | 1 |
| Badimon, JJ | 1 |
| Herbert, JM | 1 |
| Lüscher, TF | 1 |
| Anand, S | 1 |
| Yusuf, S | 1 |
| Xie, C | 1 |
| Pogue, J | 1 |
| Eikelboom, J | 1 |
| Budaj, A | 1 |
| Sussex, B | 1 |
| Liu, L | 1 |
| Guzman, R | 1 |
| Cina, C | 1 |
| Crowell, R | 1 |
| Keltai, M | 1 |
| Gosselin, G | 1 |
| Nayak, KR | 1 |
| Cavendish, JJ | 1 |
| Lorenzen, ND | 1 |
| Eldrup, N | 1 |
| Laustsen, J | 1 |
| Gardner, CD | 1 |
| Zehnder, JL | 1 |
| Rigby, AJ | 1 |
| Nicholus, JR | 1 |
| Farquhar, JW | 1 |
| Madsen, EH | 1 |
| Schmidt, EB | 1 |
| Gehr, N | 1 |
| Johannesen, NL | 1 |
| Kristensen, SR | 1 |
| Béraut, E | 1 |
| Cambou, JP | 1 |
| Guilhem, JM | 1 |
| Vaysse, N | 1 |
| Labro, S | 1 |
| Séverac, D | 1 |
| Boccalon, H | 1 |
| Bura-Rivière, A | 1 |
| Thakur, S | 1 |
| McCaslin, J | 1 |
| Ashour, H | 1 |
| Bhattacharya, V | 1 |
| Cleanthis, M | 1 |
| Daly, A | 1 |
| Srivastava, SD | 1 |
| Nagarakanti, R | 1 |
| Sodhi, S | 1 |
| Ezekowitz, M | 1 |
| Lipsitz, EC | 1 |
| Kim, S | 1 |
| Andreozzi, GM | 1 |
| Arosio, E | 1 |
| Martini, R | 1 |
| Verlato, F | 1 |
| Visonà, A | 1 |
| Deitelzweig, SB | 1 |
| Hoekstra, JW | 1 |
| Masanauskiene, E | 1 |
| Naudziūnas, A | 1 |
| Lindblad, B | 1 |
| Wakefield, TW | 1 |
| Stanley, TJ | 1 |
| Nichol, BJ | 1 |
| Greenfield, LJ | 1 |
| Stanley, JC | 1 |
| Bergentz, SE | 1 |
| Ahmadi, A | 1 |
| Maca, T | 1 |
| Stümpflen, A | 1 |
| Ugurluoglu, A | 1 |
| Ehringer, H | 1 |
| Ranke, C | 1 |
| Creutzig, A | 1 |
| Luska, G | 1 |
| Wagner, HH | 1 |
| Galanski, M | 1 |
| Bode-Böger, S | 1 |
| Frölich, J | 1 |
| Avenarius, HJ | 1 |
| Hecker, H | 1 |
| ALexander, K | 1 |
| Edmondson, RA | 1 |
| Cohen, AT | 1 |
| Das, SK | 1 |
| Wagner, MB | 1 |
| Kakkar, VV | 1 |
| Sacks, D | 1 |
| Zotz, RJ | 1 |
| Pinnau, U | 1 |
| Genth, S | 1 |
| Erbel, R | 1 |
| Meyer, J | 1 |
| Walters, TK | 1 |
| Mitchell, DC | 1 |
| Wood, RF | 1 |
| Valji, K | 1 |
| Bookstein, JJ | 1 |
| Roberts, AC | 1 |
| Sanchez, RB | 1 |
| Zeitler, E | 1 |
| Beyer-Enke, S | 1 |
| Rompel, O | 1 |
| Cimminiello, C | 1 |
| Milani, M | 1 |
| Ceriello, A | 1 |
| Motz, E | 1 |
| Yudkin, JS | 1 |
| Toplak, H | 1 |
| Bahadori, B | 1 |
| Wascher, TC | 1 |
| Marwick, C | 1 |
| Ciocon, JO | 1 |
| Galindo-Ciocon, D | 1 |
| Galindo, DJ | 1 |
| Cushman, M | 1 |
| Stampfer, MJ | 2 |
| Tracy, RP | 2 |
| Hennekens, CH | 2 |
| Jackson, MR | 1 |
| Clagett, GP | 1 |
| Balsano, F | 1 |
| Pettinger, MB | 1 |
| Waclawiw, MA | 1 |
| Davis, KB | 1 |
| Thomason, T | 1 |
| Garg, R | 1 |
| Griffin, B | 1 |
| Egan, DA | 1 |
| Quinn, MJ | 1 |
| Fitzgerald, DJ | 1 |
| Rifai, N | 1 |
| Milionis, HJ | 1 |
| Hirsch, AT | 1 |
| Ringleb, PA | 1 |
| Le Dévéhat, C | 1 |
| Khodabandehlou, T | 1 |
| Mosnier, M | 1 |
| Albert, MA | 1 |
| Langlois, M | 1 |
| Duprez, D | 1 |
| Delanghe, J | 1 |
| De Buyzere, M | 1 |
| Clement, DL | 1 |
| Scheen, AJ | 1 |
| Neilipovitz, DT | 1 |
| Bryson, GL | 1 |
| Nichol, G | 1 |
| Olin, JW | 2 |
| Black, C | 1 |
| Paterson, KR | 1 |
| Agnelli, G | 1 |
| Duran, E | 1 |
| Canbaz, S | 1 |
| Ege, T | 1 |
| Acipayam, M | 1 |
| Donnelly, R | 1 |
| Yeung, JM | 1 |
| Johnson, WC | 1 |
| Williford, WO | 1 |
| Goldhaber, SZ | 1 |
| Manson, JE | 1 |
| LaMotte, F | 1 |
| Rosner, B | 1 |
| Buring, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982] | 1,500 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268] | Phase 4 | 72 participants (Actual) | Interventional | 2019-04-24 | Completed | ||
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| Perioperative Blood Pressure and In-hospital Morbidity After Coronary Artery Bypass Surgery[NCT05192005] | 1,220 participants (Anticipated) | Observational | 2023-04-15 | Not yet recruiting | |||
| Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| A Double-blind, Randomized Study of Clopidogrel 75 mg/d vs Placebo, on a Background of ASA 75-100 mg/d,in Peripheral Arterial Disease (PAD) Patients Receiving a Unilateral Below Knee Bypass Graft.[NCT00174759] | Phase 3 | 1,460 participants (Anticipated) | Interventional | 2004-09-30 | Completed | ||
| [NCT00035776] | 0 participants | Observational | 2001-01-31 | Completed | |||
| A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817] | Phase 3 | 15,603 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| A Phase III Randomized Trial of Warfarin Plus Antiplatelet Therapy Versus Antiplatelet Therapy Alone in Patients With Peripheral Vascular Disease[NCT00125671] | Phase 3 | 2,400 participants | Interventional | 2000-01-31 | Active, not recruiting | ||
| Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb[NCT04229264] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-01-09 | Recruiting | ||
| DUAL Pathway Inhibition (Low-dose Rivaroxaban and Aspirin) as Compared to Aspirin Only to Improve Endothelial Function in Peripheral Artery Disease.[NCT04218656] | Phase 4 | 159 participants (Actual) | Interventional | 2020-06-08 | Completed | ||
| The Protective Effect of Ginkgo Biloba Extract on Cisplatin-Induced Ototoxicity in Humans Beings Evaluated by Distortion Product Otoacoustic Emissions[NCT01139281] | Phase 2 | 15 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705] | 2,927 participants (Actual) | Observational | 2019-09-20 | Completed | |||
| Antiplatelet Therapy in HIV - Antiplatelet and Immune Modulating Effects of Aspirin or Clopidogrel in Subjects With HIV[NCT02559414] | Phase 2 | 55 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028] | 100 participants (Anticipated) | Observational | 2021-03-10 | Not yet recruiting | |||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862] | 350 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease[NCT02719665] | 30 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Arterial Imaging of Inflammation and Resolution After Endovascular Surgery[NCT03590769] | Phase 1 | 9 participants (Actual) | Interventional | 2017-06-01 | Completed | ||
| [NCT00005496] | 0 participants | Observational | 1998-09-30 | Completed | |||
| [NCT00000500] | Phase 3 | 0 participants | Interventional | 1981-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to endothelial function. (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 14.06 |
| Placebo Follow up | 13.84 |
| Aspirin Baseline | 11.18 |
| Aspirin Randomization | 12.11 |
| Clopidogrel Baseline | 13.06 |
| Clopidogrel Randomization | 12.29 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to immune activity (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 15.53 |
| Placebo Follow up | 15.43 |
| Aspirin Baseline | 13.15 |
| Aspirin Follow up | 14.96 |
| Clopidogrel Baseline | 16.03 |
| Clopidogrel Follow up | 14.85 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to inflammation (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
(NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
The primary objective of these analyses will be to compare the effects of aspirin versus control and clopidogrel versus control for the outcome of platelet activity. Aspirin is expected to decrease arachidonic acid-induced platelet aggregation by 50% versus control. Clopidogrel is expected to decrease ADP-induced platelet aggregation by 50% versus control. (NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 72.35 |
| Placebo Follow up | 79.11 |
| Aspirin Baseline | 72.79 |
| Aspirin Randomization | 26.77 |
| Clopidogrel Baseline | 71.07 |
| Clopidogrel Randomization | 65.00 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
38 reviews available for aspirin and Peripheral Vascular Diseases
| Article | Year |
|---|---|
Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials.
Topics: Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Intracranial Hemorrhages; Myocardial Infarction; P | 2017 |
Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery.
Topics: Anastomosis, Surgical; Anticoagulants; Arteriosclerosis; Aspirin; Dipyridamole; Graft Occlusion, Vas | 2015 |
Aspirin, Plavix, and Other Antiplatelet Medications: What the Oral and Maxillofacial Surgeon Needs to Know.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Medication Therapy Management; Oral Surgical | 2016 |
Acute and long-term antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Plate | 2008 |
Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Cardiovascular Diseas | 2009 |
Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Evidence-Based Me | 2009 |
Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.
Topics: Aspirin; Cardiovascular Diseases; Dipyridamole; Humans; Peripheral Vascular Diseases; Platelet Aggre | 2009 |
Women and peripheral arterial disease.
Topics: Age Factors; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Biomarkers; C-Reactive Protein; Card | 2009 |
Antiplatelet and antithrombotic treatment of patients with peripheral arterial disease.
Topics: Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Disease Progression; Dose-Respo | 2010 |
[Thrombosis and antithrombotic agents in peripheral artery disease].
Topics: Administration, Oral; Anticoagulants; Aspirin; Fibrinolytic Agents; Humans; Intermittent Claudicatio | 2002 |
High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
Topics: Arteriosclerosis; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Coronary Disease; Female; Fi | 2003 |
Antiplatelet drugs in cardiovascular diseases.
Topics: Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Drug Resistance; Humans; Myocardial Infarctio | 2003 |
Antiplatelet therapy in peripheral arterial disease.
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Dipyridamole; Humans; Peripheral Vascular Disease | 2004 |
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Topics: Administration, Oral; Angina Pectoris; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopido | 2004 |
Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment.
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Dipyridamole; Humans; Peripheral Vascular Diseases; P | 2005 |
Cardiovascular risk prevention in peripheral artery disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Drug Therapy, Combination; Humans | 2005 |
[The guideline 'Diagnosis and treatment of peripheral artery disease of the lower extremities' of The Netherlands Surgical Society].
Topics: Aspirin; Humans; Leg; Netherlands; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Pr | 2005 |
Emerging drugs in peripheral arterial disease.
Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Arteries; Aspirin; Clopidogrel; D | 2006 |
Masterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudication.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Intermittent Claudication; | 2006 |
Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Diabetic Angiopathies; Humans; Hydroxymethy | 2007 |
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.
Topics: Angina, Unstable; Aspirin; Atherosclerosis; Biomarkers; Blood Platelets; Clopidogrel; Humans; Inflam | 2007 |
Risk reduction with clopidogrel in the management of peripheral arterial disease.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Peripheral Vascular Diseases; Platelet Aggr | 2007 |
[Antiplatelet and anticoagulant treatment after percutaneous transluminal angioplasty for peripheral arteriosclerosis. Survey of a Cochrane review].
Topics: Angioplasty, Balloon; Anticoagulants; Arteriosclerosis; Aspirin; Dipyridamole; Evidence-Based Medici | 2007 |
Antiplatelet therapy for vascular interventions.
Topics: Angioplasty, Balloon; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Endarterecto | 2008 |
Chronic antithrombotic therapy in post-myocardial infarction patients.
Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Clopidogrel; Humans; Myocardial Infarction; Perip | 2008 |
Peripheral arterial disease and the hospitalist: the rationale for early detection and optimal therapy.
Topics: Aspirin; Early Diagnosis; Hospitalists; Humans; Peripheral Vascular Diseases; Platelet Aggregation I | 2008 |
[Peripheral arterial disease--an underappreciated clinical problem].
Topics: Age Factors; Aged; Ankle; Aspirin; Atherosclerosis; Brachial Artery; Diabetes Complications; Dyslipi | 2008 |
Diabetes mellitus and peripheral vascular disease: is aspirin effective in preventing vascular events?
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Diabetes Complications; Diabetic Angiop | 1996 |
Antithrombotic therapy in peripheral arterial occlusive disease.
Topics: Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Endarterectomy, C | 1998 |
Rationale for the use of antiplatelet drugs in patients with peripheral vascular disease.
Topics: Arteriosclerosis; Aspirin; Clinical Trials as Topic; Disease Progression; Humans; Intermittent Claud | 1994 |
Ticlopidine and clopidogrel.
Topics: Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Angina, Unstable; Aspirin; Bo | 1999 |
The role of C-reactive protein in cardiovascular disease risk.
Topics: Arteriosclerosis; Aspirin; Biomarkers; C-Reactive Protein; Coronary Disease; Female; Humans; Male; P | 1999 |
The effect of perioperative aspirin therapy in peripheral vascular surgery: a decision analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Decision Support Techniques; Hemorrhage; Humans; I | 2001 |
New antiplatelet agents: ticlopidine and clopidogrel. Antiplatelet therapy but at what cost?
Topics: Aspirin; Bone Marrow; Clopidogrel; Humans; Peripheral Vascular Diseases; Platelet Aggregation Inhibi | 2001 |
Rationale for the use of platelet aggregation inhibitors in PAD patients.
Topics: Aspirin; Clopidogrel; Humans; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Randomi | 2001 |
Management of intermittent claudication: the importance of secondary prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Blood Pressure; Coronary Disease; | 2002 |
Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy.
Topics: Algorithms; Arteriosclerosis; Aspirin; Clopidogrel; Humans; Peripheral Vascular Diseases; Platelet A | 2002 |
The role of platelets in peripheral arterial disease: therapeutic implications.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Peripheral Vascular Diseases; | 2002 |
36 trials available for aspirin and Peripheral Vascular Diseases
| Article | Year |
|---|---|
Inter-arm blood pressure difference and mortality: a cohort study in an asymptomatic primary care population at elevated cardiovascular risk.
Topics: Arm; Aspirin; Blood Pressure; Blood Pressure Determination; Body Mass Index; Cross-Sectional Studies | 2016 |
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.
Topics: Adult; Aged; Antioxidants; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic A | 2008 |
Patients with peripheral arterial disease in the CHARISMA trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Epidemiologic Method | 2009 |
Variability of non-response to aspirin in patients with peripheral arterial occlusive disease during long-term follow-up.
Topics: Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Aspirin; Drug Resistance; Female; Follo | 2009 |
Randomized controlled trial of aspirin and clopidogrel versus aspirin and placebo on markers of smooth muscle proliferation before and after peripheral angioplasty.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Biomarkers; Blotting, Western; Cell P | 2009 |
Bleeding increases the risk of ischemic events in patients with peripheral arterial disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cerebral Hemorrhage; Confide | 2009 |
Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y.
Topics: Aged; Aged, 80 and over; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Catheterization, Per | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients.
Topics: Administration, Oral; Aged; Aspirin; Cardiovascular Diseases; Chi-Square Distribution; Clopidogrel; | 2012 |
Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Ankle; Arterial Occlusi | 2003 |
Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysi
Topics: Aged; Alanine; Aspirin; Cerebrovascular Disorders; Coronary Disease; Double-Blind Method; Drug Thera | 2003 |
The effect of a loading dose (300 mg) of clopidogrel on platelet function in patients with peripheral arterial disease.
Topics: Aged; Aspirin; Blood Platelets; Cell Size; Clopidogrel; Drug Resistance; Female; Humans; Male; Middl | 2003 |
Combination antiplatelet therapy in patients with peripheral vascular bypass grafts.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Drug T | 2004 |
Leukocyte count as an independent predictor of recurrent ischemic events.
Topics: Aspirin; Biomarkers; Brain Ischemia; Cause of Death; Clopidogrel; Female; Humans; Inflammation; Leuk | 2004 |
The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease.
Topics: Adenosine Diphosphate; Aged; Arteriosclerosis; Aspirin; Blood Platelets; Cell Shape; Clopidogrel; Dr | 2004 |
Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study.
Topics: Adult; Aged; Aspirin; Diabetic Angiopathies; Double-Blind Method; Female; Follow-Up Studies; Humans; | 2004 |
Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Biomarkers; Clopidogrel; Collagen; Cross-Ove | 2005 |
Overcoming aspirin resistance: increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease.
Topics: Aged; Aged, 80 and over; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Cardiovascular Disea | 2006 |
Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Antithrombin III; Aspirin; Blood Platelets; C-Reactive Protein; CD40 Ligand | 2006 |
Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial.
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Dalteparin; Drug Therapy, Combinat | 2006 |
Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Humans; Ischemia; Leg; Male; Peripheral Vascular Disease | 2007 |
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial.
Topics: Aged; Aspirin; Blood Platelets; Cardiovascular Agents; Double-Blind Method; Drug Therapy, Combinatio | 2007 |
Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty.
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Combined Modality Therapy; Dose-Re | 1995 |
Controlled trial of high- versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease.
Topics: Aged; Angioplasty, Balloon; Aspirin; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; | 1994 |
Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting.
Topics: Adult; Aged; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Femoral Artery; Graft Occlusi | 1994 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A comparison between aspirin and pentoxifylline in relieving claudication due to peripheral vascular disease in the elderly.
Topics: Aged; Aspirin; Female; Humans; Intermittent Claudication; Male; Pentoxifylline; Peripheral Vascular | 1997 |
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In | 1998 |
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In | 1998 |
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In | 1998 |
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In | 1998 |
Compliance to multiple interventions in a high risk population.
Topics: Adult; Aged; Anticholesteremic Agents; Anticoagulants; Antioxidants; Aspirin; Data Interpretation, S | 1999 |
Clinical efficacy of an automated high-sensitivity C-reactive protein assay.
Topics: Aged; Aged, 80 and over; Antioxidants; Aspirin; beta Carotene; C-Reactive Protein; Case-Control Stud | 1999 |
Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.
Topics: Aspirin; Brain Ischemia; Cause of Death; Clopidogrel; Confidence Intervals; Double-Blind Method; Fem | 2000 |
The effect of perioperative aspirin therapy in peripheral vascular surgery: a decision analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Decision Support Techniques; Hemorrhage; Humans; I | 2001 |
Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Blood Vessel Prosthesis; Boston; Combined Modal | 2002 |
Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Double-Blind Method; Humans; Male; Middle Aged; Peripheral | 1992 |
73 other studies available for aspirin and Peripheral Vascular Diseases
| Article | Year |
|---|---|
[PEGASUS or COMPASS? A guide for a wise clinical choice.]
Topics: Aspirin; Cerebrovascular Disorders; Clinical Decision-Making; Clinical Protocols; Drug Administratio | 2019 |
Digital ischaemia secondary to adalimumab-induced antiphospholipid syndrome.
Topics: Adalimumab; Anti-Inflammatory Agents; Antiphospholipid Syndrome; Aspirin; Crohn Disease; Female; Han | 2020 |
Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Case-Control Studies; Clopidogrel; Diabete | 2021 |
Prevalence of nonresponsiveness to aspirin in patients with symptomatic peripheral arterial disease using true point of care testing.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Male; Peripheral Vascular Diseases; Pla | 2014 |
Initial experience with ticagrelor in patients with critical limb ischemia and high on-clopidogrel platelet reactivity undergoing complex peripheral endovascular procedures.
Topics: Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Endovascular Procedures | 2014 |
Decade in review--peripheral vascular disease: 10 Years of breakthroughs in peripheral vascular disease.
Topics: Anticoagulants; Aspirin; Endarterectomy; Endovascular Procedures; Exercise Therapy; Humans; Peripher | 2014 |
Usefulness of hypertensive blood pressure response during a single-stage exercise test to predict long-term outcome in patients with peripheral arterial disease.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Blood Pressure; Cardiovascular Diseases; Cause of Death; | 2008 |
Prognostic value of hypotensive blood pressure response during single-stage exercise test on long-term outcome in patients with known or suspected peripheral arterial disease.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Blood Pressure; Cardiovascular Diseases; Exercise Test; | 2008 |
POPADAD trial. Time for a proper study of aspirin after a vascular event?
Topics: Aspirin; Diabetic Angiopathies; Humans; Periodicals as Topic; Peripheral Vascular Diseases; Platelet | 2008 |
POPADAD trial. Don't stop taking aspirin.
Topics: Aspirin; Diabetic Angiopathies; Humans; Peripheral Vascular Diseases; Platelet Aggregation Inhibitor | 2008 |
Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?
Topics: Antioxidants; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Humans; Pe | 2009 |
Aspirin and secondary prevention in peripheral artery disease: a perspective for the early 21st century.
Topics: Aspirin; Cardiovascular Diseases; Humans; Peripheral Vascular Diseases; Platelet Aggregation Inhibit | 2009 |
Profile of cardiovascular risk factors and mortality in patients with symptomatic peripheral arterial disease.
Topics: Aged; Aspirin; Brazil; Coronary Artery Disease; Female; Humans; Hypertension; Kaplan-Meier Estimate; | 2009 |
Aspirin for prevention of stroke and cardiovascular events among patients with peripheral artery disease.
Topics: Aspirin; Cardiovascular Diseases; Dipyridamole; Humans; Peripheral Vascular Diseases; Platelet Aggre | 2009 |
Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2010 |
Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2010 |
Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2010 |
Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2010 |
Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Brain Ischemia; Clini | 2009 |
Medication underuse during long-term follow-up in patients with peripheral arterial disease.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Cardiovascular Agents; Drug Therapy, Combination; Eviden | 2009 |
An aspirin a day: are we barking up the wrong willow tree?
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Therapy, Com | 2010 |
Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
Topics: Adult; Aged; Aged, 80 and over; Ankle Brachial Index; Aspirin; Cardiovascular Agents; Cardiovascular | 2010 |
Aspirin for prevention of cardiovascular events in individuals with low ankle brachial index.
Topics: Ankle; Aspirin; Atherosclerosis; Cardiovascular Diseases; Data Interpretation, Statistical; Humans; | 2010 |
[Uncertain benefit of low dosage ASA in peripheral arterial disease. Low dosage in symptomatic--individual assessment in asymptomatic disease].
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Evidence-Based Medicine; Fibrino | 2010 |
[Thrombotic microangiopathy after extracorporeal circulation: important differential diagnosis].
Topics: ADAM Proteins; ADAMTS13 Protein; Aged, 80 and over; Aortic Diseases; Aspirin; Coma; Critical Care; D | 2011 |
An assessment of the concentration-related prognostic value of cardiac troponin I following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; A | 2011 |
Review of an article: Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. Jill J.F. Belch, MD, FRCP, John Dormandy, MD, FRCS, and the CASPAR Writing Committee
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Female; Humans; Lower Extremity; Male; Peripheral Vas | 2012 |
Prescribing patterns of antiplatelet agents are highly variable after lower extremity endovascular procedures.
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Prescriptions; Drug Therapy | 2013 |
Assessment of platelet activation after exercise using a standardized whole blood flow cytometry assay.
Topics: Aged; Antibodies, Monoclonal; Aspirin; Coronary Disease; Exercise Test; Female; Flow Cytometry; Huma | 2002 |
Is aspirin still the antiplatelet drug of choice for patients with peripheral arterial disease?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Peripheral Vascul | 2003 |
[Anticoagulation and antiaggregation in patients with peripheral arterial occlusive diseases].
Topics: Administration, Oral; Angioplasty, Balloon; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Bl | 2003 |
Value of thromboelastography in the assessment of platelet function.
Topics: Adenosine Diphosphate; Aspirin; Humans; Peripheral Vascular Diseases; Platelet Aggregation; Platelet | 2003 |
Aspirin for cardiovascular disease prevention.
Topics: Aspirin; Atrial Fibrillation; Coronary Disease; Heart Valve Prosthesis; Humans; Myocardial Infarctio | 2003 |
Veterans Affairs (VA) Cooperative Study #362.
Topics: Aspirin; Cohort Studies; Female; Graft Rejection; Graft Survival; Hospitals, Veterans; Humans; Male; | 2003 |
Influence of systemic inflammation on efficiency of antiplatelet therapy in PAOD patients.
Topics: Arterial Occlusive Diseases; Aspirin; C-Reactive Protein; Female; Humans; Inflammation; Male; Periph | 2004 |
The efficacy of aspirin in patients undergoing infra-inguinal bypass and identification of high risk patients.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis Implantation; Graft Occlusion, Vasc | 2003 |
Picotamide versus aspirin in diabetic patients with peripheral arterial disease: has David defeated Goliath?
Topics: Arteries; Aspirin; Diabetic Angiopathies; Humans; Peripheral Vascular Diseases; Phthalic Acids; Plat | 2004 |
Clinical and angiographic outcome after interventional treatment of the iliac arteries with a new carbofilm coated stent: preliminary results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiography; Anticoagulants; Arterial Occlusive Disea | 2004 |
Creative cost-effectiveness analysis of CAPRIE data- dust in our eyes.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Humans; Peripheral Vascular | 2005 |
[Antiplatelet agents and regional anaesthesia: experience in 130 patients].
Topics: Aged; Aspirin; Autonomic Nerve Block; Blood Loss, Surgical; Blood Vessel Prosthesis Implantation; Cl | 2005 |
Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease.
Topics: Aged; Alleles; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Clopidogrel; Cohort Studies; Ex | 2005 |
The (variable) definition of benefit in the case of clopidogrel vs aspirin.
Topics: Aspirin; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregat | 2005 |
Use of ankle brachial index screening for selecting patients for antiplatelet drug therapy.
Topics: Ankle; Aspirin; Blood Gas Monitoring, Transcutaneous; Brachial Artery; Coronary Disease; Humans; Per | 2005 |
Medical management of peripheral arterial disease.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Humans; Peripheral Vascular Diseases; Phthalic Acids; P | 2006 |
Treatment practices and outcomes of patients with established peripheral arterial disease hospitalized with acute myocardial infarction in a community setting.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Female; Hospit | 2007 |
[Impact of the choice of an antiplatelet therapy for peripheral arterial disease: cost-effectiveness ratio and health economics assessment].
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Humans; Peripheral Vascular Diseases; Platelet Aggregat | 2007 |
The efficacy of aspirin in peripheral arterial disease: an unresolved question.
Topics: Aspirin; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Reproducibility of Results | 2007 |
TNF-alpha -308G>A polymorphism modulates cytokine serum concentrations and macrovascular complications in diabetic patients on aspirin.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Coronary Disease; Cytokines; Diabetes Mellitus, Type 2; Di | 2007 |
Prognostic value of ankle-brachial index and dobutamine stress echocardiography for cardiovascular morbidity and all-cause mortality in patients with peripheral arterial disease.
Topics: Aged; Ankle; Aspirin; Blood Pressure; Brachial Artery; Cardiovascular Diseases; Coronary Artery Dise | 2007 |
Testing aspirin resistance using the Platelet Function Analyzer-100: some methodological caveats and considerations.
Topics: Artifacts; Aspirin; Blood Platelets; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Resistance; F | 2008 |
[Medical treatment of patients with clinical peripheral arterial disease at hospital discharge: compliance with the French guidelines and changing practices (COPART I registry)].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensins; Aspirin; Cohort Studies; Drug Pr | 2008 |
Increased platelet-monocyte aggregation in male claudicants with the Pl(A1/A2) polymorphism of Gp IIb/IIIa.
Topics: Aged; Aspirin; Blood Platelets; Female; Flow Cytometry; Gene Frequency; Genotype; Humans; Intermitte | 2008 |
Commentary on "Antiplatelet therapy for vascular interventions".
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Peripheral Vascular Diseases; Platelet A | 2008 |
Antithrombotic therapy in peripheral arterial disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cilostazol; Clopidogrel; Comorbidity; Diabetic Angiopathie | 2008 |
Consensus document on intermittent claudication from the Central European Vascular Forum 1st edition - Abano Terme (Italy) - May 2005 2nd revision - Portroz (Slovenia) September 2007.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Disease Progression; Exercise Test; Humans; Intermittent Cla | 2008 |
Pharmacological prophylaxis against postoperative graft occlusion after peripheral vascular surgery: a world-wide survey.
Topics: Anticoagulants; Aspirin; Data Collection; Dipyridamole; Drug Utilization; Graft Occlusion, Vascular; | 1995 |
How important is aspirin therapy following balloon angioplasty of peripheral arteries?
Topics: Angioplasty, Balloon; Aspirin; Humans; Peripheral Vascular Diseases | 1994 |
Left atrial thrombi despite anticoagulant and antiplatelet therapy.
Topics: Aged; Aspirin; Atrial Fibrillation; Dilatation, Pathologic; Echocardiography; Echocardiography, Tran | 1994 |
Low-dose aspirin fails to inhibit increased platelet reactivity in patients with peripheral vascular disease.
Topics: Aged; Aspirin; Blood Coagulation; Blood Platelets; Collagen; Drug Administration Schedule; Female; H | 1993 |
Occluded peripheral arteries and bypass grafts: lytic stagnation as an end point for pulse-spray pharmacomechanical thrombolysis.
Topics: Adult; Aged; Aspirin; Catheterization; Female; Graft Occlusion, Vascular; Humans; Leg; Male; Middle | 1993 |
Indications and results after Strecker-stent-application in iliac and SFA.
Topics: Arterial Occlusive Diseases; Aspirin; Female; Femoral Artery; Follow-Up Studies; Heparin; Humans; Il | 1993 |
Prevention of vascular events in diabetes mellitus: which "antithrombotic" therapy?
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Fibrinolytic Agents | 1996 |
Assessing the evidence on aspirin in diabetes mellitus. Gemini or Libra; lumping or splitting; surrogate or hard; low or high; interventionist or nihilist.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Diabetes Complications; Diabetic Angiop | 1996 |
CAPRIE trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; P | 1997 |
CAPRIE trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; P | 1997 |
Aspirin's role in prevention now official.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Pla | 1997 |
[Myocardial infarct, stroke and vascular events reduced by a third].
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular | 1997 |
[Prevention in the 21st century. Athero-thrombosis and ischemic events].
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Female; Forecasting; Human | 1998 |
Mechanism underlying increased platelet reactivity in patients with peripheral arterial disease.
Topics: Anticoagulants; Aspirin; Blood Platelets; Fibrinogen; Heparin; Humans; Peripheral Vascular Diseases; | 1999 |
Effect of naftidrofuryl on platelet aggregation in plasma from aspirin treated patients: an in vitro study.
Topics: Aged; Aged, 80 and over; Aspirin; Diabetic Angiopathies; Drug Interactions; Female; Humans; Male; Mi | 2000 |
Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention.
Topics: Aspirin; Carotid Stenosis; Cost-Benefit Analysis; Diabetes Mellitus; Digestive System; Female; Human | 2000 |
Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis.
Topics: Aged; Arteriosclerosis; Ascorbic Acid; Aspirin; C-Reactive Protein; Female; Fibrinogen; Humans; Hype | 2001 |
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Clopidogrel; Coronary Disease; D | 2001 |
Antiplatelet therapy: a vascular medicine perspective.
Topics: Aspirin; Humans; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Ticlopidine; United | 2000 |
Antiplatelet therapy: a vascular medicine perspective.
Topics: Aspirin; Clopidogrel; Humans; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Ticlopi | 2000 |
Aspirin versus clopidogrel for synthetic graft patency after peripheral arterial bypass grafting.
Topics: Arteries; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Graft Occlusion, Vascular; Humans; Male; Pe | 2001 |